AI Article Synopsis
- The study estimates the total cost of cancer in Europe for 2018 at €199 billion, incorporating health expenditures and productivity losses.
- Health care spending on cancer reached €103 billion, with €32 billion specifically for cancer drugs, while informal care costs accounted for €26 billion.
- Although mortality-related productivity loss decreased due to improved survival rates, the overall increase in spending has outpaced the rise in cancer incidence over the past two decades.
Article Abstract
Background: Cancer care is evolving rapidly, and costs and value of new treatments are frequently debated. Up-to-date evidence on the total cost of cancer is needed to inform policy decisions. This study estimates the cost of cancer in Europe in 2018 and extends a previous analysis for 1995-2014.
Methods: Cancer-specific health expenditure were derived from national estimates. Data on cancer drug sales were obtained from IQVIA. The productivity loss from premature mortality was estimated from data from Eurostat and the World Health Organization. Estimates of the productivity loss from morbidity and informal care costs were based on previous studies.
Findings: The total cost of cancer was €199 billion in Europe (EU-27 plus Iceland, Norway, Switzerland, and the United Kingdom) in 2018. Total costs ranged from €160 per capita in Romania to €578 in Switzerland (after adjustment for price differentials). Health expenditure on cancer care were €103 billion, of which €32 billion were spent on cancer drugs. Informal care costs were €26 billion. The total productivity loss was €70 billion, composed of €50 billion from premature mortality and €20 billion from morbidity.
Interpretation: Health expenditure on cancer care were of a similar magnitude as the sum of non-health-care costs in 2018. Over the last two decades, health spending on cancer has increased faster than the increase in cancer incidence. The productivity loss from premature mortality has decreased because of reductions in mortality in the working-age population. Trends in informal care costs and productivity loss from morbidity are uncertain because of lack of comparable data.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejca.2020.01.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol for generating splice isoform-specific mouse mutants using CRISPR-Cas9 and a minigene splicing reporter.
STAR Protoc
January 2025
Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Electronic address:
Here, we present a protocol to alter the production of alternatively spliced mRNA variants, without affecting the overall gene expression, through CRISPR-Cas9-engineered genomic mutations in mice. We describe steps for designing guide RNA to direct Cas9 endonuclease to consensus splice sites, producing transgenic mice through pronuclear injection, and screening for desired mutations in cultured mammalian cells using a minigene splicing reporter. Splice isoform-specific mouse mutants provide valuable tools for genetic analyses beyond loss-of-function and transgenic alleles.
View Article and Find Full Text PDFThe Translation Initiation Factor eIF2Bα Regulates Development, Stress Response, Amylase Production, and Kojic Acid Synthesis in the Fungus Aspergillus oryzae.
Curr Microbiol
January 2025
Engineering Technological Center of Fungus Active Substances of Fujian Province, College of Biological Sciences and Technology, Minnan Normal University, Zhangzhou, 363000, China.
Translation initiation, which involves numerous protein factors and coordinated control steps, represents the most complicated process during eukaryotic translation. However, the roles of eukaryotic translation initiation factor (eIF) in filamentous fungi are not well clarified. In this study, we investigated the function of eIF2Bα in Aspergillus oryzae, an industrially important filamentous fungus.
View Article and Find Full Text PDFChrysoeriol: a natural RANKL inhibitor targeting osteoclastogenesis and ROS regulation for osteoporosis therapy.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
The Key Laboratory of Spine and Spinal Cord Disease of Jiangxi Province, Nanchang, 330006, China.
Chrysoeriol (CHE) is a naturally occurring compound with established anti-inflammatory and anti-tumor effects. This study examines its potential role in regulating osteoclast differentiation and activity, both of which are crucial for bone remodeling. Computational docking revealed high binding affinity between CHE and RANKL, specifically at the Lys-181 residue of RANKL, suggesting potential inhibitory interactions on osteoclastogenesis.
View Article and Find Full Text PDFBK Polyomavirus and acute kidney injury in transplant recipients: signaling pathways and molecular mechanisms.
Virol J
January 2025
Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Acute kidney injury (AKI) is a condition that can result in changes in both urine production and creatinine levels in the bloodstream, complicating the treatment process and worsening outcomes for many hospitalized patients. BK polyomavirus (BKPyV), a member of the Polyomaviridae family, is prevalent in the population and remains latent in the body. It can reactivate in individuals with a compromised immune system, particularly post-kidney transplant, and can activate various transcription factors and immune mediators.
View Article and Find Full Text PDFClinical outcomes of closed versus open simple ankle fractures patterns requiring soft tissue reconstruction: A prospective comparative observational study.
Foot Ankle Surg
December 2024
Dept of Orthopaedics, Kings College Hospital MTC, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Background: Contemporary guidelines advocate for initial debridement and single-stage definitive fixation with immediate soft tissue reconstruction for open fractures. This study aims to evaluate the effectiveness of single-stage stabilization and immediate definitive soft tissue coverage in open ankle fractures compared to closed fractures.
Methods: We compared all isolated open ankle fractures (OF) treated between January 2017 and June 2019 to a control group of operatively managed closed ankle fractures (CF).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!